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Abstract 
To investigate the vasoconstrictor effect of 5-HT1B/1D receptor agonists for migraine treatment, 
changes in cerebral blood flow (CBF) and blood volume induced by rizatriptan were assessed 
by PET. Eleven healthy volunteers underwent PET studies before and after rizatriptan 
administration. Dynamic PET data were acquired after bolus injection of H215O to analyze CBF 
and arterial-to-capillary blood volume (V0) images using the 3-weighted integral method. 
Following a baseline scan, three further acquisitions were performed at 40-50, 60 and 70-80 
min after drug administration. Global and regional differences in CBF and V0 between 
conditions were compared using absolute values in the whole brain and cortical regions, as well 
as Statistical Parametric Mapping (SPM) analysis. The global and regional values for CBF and 
V0 decreased significantly after rizatriptan administration compared with the baseline condition. 
However, both values recovered to baseline within 80 min after treatment. The maximal 
reduction in global CBF and V0 was about 13 % of baseline value. The greatest decrease in 
CBF was observed about 60 min after drug administration, whereas the maximal reduction in 
V0 was observed about 5 min earlier. SPM did not highlight any regional differences between 
conditions. Thus in brain circulation, rizatriptan caused significant CBF and V0 decreases which 
are consistent with the vasoconstrictor effect of triptans on the large cerebral arteries. The 
gradual recovery in the late phase from the maximal CBF and V0 decrease suggests that 
rizatriptan does not affect the cerebral autoregulatory response in small arteries induced by CBF 
reduction. 
 
Keywords: cerebral blood flow, arterial-to-capillary blood volume, 5-HT1B/1D receptor, 
rizatriptan, vasoconstriction, positron emission tomography 
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INTRODUCTION 
Triptans, 5-HT1B/1D receptor agonists used as rapid antimigraine treatment drugs, are 
known to act by means of the vasoconstrictor effect of 5-HT1B receptors on the cranial arteries 
and of the inhibitory effect of 5-HT1D receptors on the trigeminal terminals (De Vries et al., 
1999a; Tepper et al., 2002). The vasoconstrictor effect increases the resistance of carotid 
arteries and reduces cerebral blood flow (CBF) (Feniuk et al., 1989; den Boer et al., 1991; De 
Vries et al., 1999b). Cerebral vessels are assumed to dilate during migraine headache and CBF 
changes during migraine attacks as reported by Olesen et al. (1990). The therapeutic 
vasoconstrictor effect of triptans presumably acts by counterbalancing the vasodilation of major 
vessels that might be responsible to induce headache. On the other hand, the flow-induced 
vasodilation in peripheral circulation is not affected by these drugs (Feniuk et al., 1989; 
Williamson et al., 1997; de Hoon et al., 2000). Although patients with migraine did not show 
changes in CBF after treatment with sumatriptan (Friberg et al., 1991), triptans may induce 
small changes in CBF and blood volume as a result of vasoconstriction in the major cerebral 
arteries, followed by reduction in arterial perfusion pressure. Direct measurement of changes in 
CBF and intra-cerebral vascular volume induced by triptans in normal circulation would 
provide hemodynamic information about changes occurring after administration of triptans. 
The purpose of the current study was to investigate the vasoconstrictor effect of triptans 
by analyzing the time-dependent changes in cerebral hemodynamic parameters in healthy 
volunteers. Oral dose of rizatriptan, one of the agents known to act as 5-HT1B/1D receptor 
agonist, was used to reproduce the effect of triptans. H215O PET was performed to measure 
CBF and arterial-to-capillary blood volume (V0) using the bolus injection method. Changes in 




MATERIALS AND METHODS 
 
Subjects 
Eleven healthy male volunteers, aged 20 to 31 years (mean = 23.5 ± 3.2), were recruited 
for the H215O PET study. Two of them had an experience of migraine-like headache, and the 
rest of them never suffered any migraine. Before the study, they gave their written informed 
consent to undergo PET scans before and after oral administration of rizatriptan. The study was 
approved by the Ethical Committee of the University of Fukui, Faculty of Medical Science. 
 
PET procedures 
All subjects underwent PET scans with a whole-body tomography scanner (ADVANCE, 
General Electric Medical System, Milwaukee, WI), which allows simultaneous acquisition of 
35 image slices with inter-slice spacing of 4.25 mm (DeGrado et al., 1994). Performance tests 
showed the intrinsic resolution of the scanner to be 4.6 to 5.7 mm in the transaxial direction and 
4.0 to 5.3 mm in the axial direction. A transmission scan was performed using 68Ge /68Ga for 
attenuation correction in each subject before the tracer administration. The PET data were 
reconstructed using a Hanning filter with a resolution of 6.0-mm full width at half maximum 
(FWHM) in the transaxial direction. 
The subjects were positioned on the scanner bed with their heads immobilized using a 
head holder. A small cannula was placed in the right brachial artery for blood sampling. PET 
scans for both CBF and V0 were performed before and 40-80 min after rizatriptan 
administration using the bolus H215O injection method. Rizatriptan (10 mg, orally disintegrating 
tablet) was administered after the baseline scan. Following baseline scan, all subjects underwent 
three further scans at 40 or 50 min, at 60 min and at 70 or 80 min after treatment. The interval 
between each of the scans after treatment was 10-20 min, including scanning time. 
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As for CBF measurement, a 3-min dynamic PET scan was started at the time of the bolus 
H215O injection (555-740 MBq) from the left antecubital vein with frame durations of 5 sec × 
12, 10 sec × 6 and 20 sec × 3. Radioactivity in the arterial blood was counted continuously 
using an automatic blood sampling system (ABSS) which includes a positron radioactive 
counter (Apollomec Co. Ltd., Kobe, Japan) and a Bio-minipump (AC-2120; Atto Co., Tokyo, 
Japan). Arterial blood was sampled and counted continuously with the ABSS at a constant rate 
of 7 mL/min for the first 2 min, followed by manual sampling of 0.5 mL of blood every 20 sec 
during the remaining scan time. Radioactivity counted by the ABSS was calibrated with the 
blood sampled manually. Decay of the radioactivity from PET and blood data was corrected to 
the starting point of each scan, and dispersion for the external tube in the arterial curves was 
corrected with the double-exponential dispersion function described elsewhere (Okazawa et al., 
2002). During the PET scanning, the arterial tensions for CO2 (PaCO2) and O2 (PaO2), as well as 
the hematocrit (Ht), pH, and total arterial O2 content (tO2c) were measured from the same blood 
sample. Blood pressure of each subject was monitored continuously through the arterial line 
and displayed on a monitor during the PET study. 
 
Calculation of parametric images 
CBF (mL min-1 100g-1) image was calculated from the dynamic PET data and arterial 
blood curves by means of the 3-weighted integral (3-WI) method. The calculation procedure for 
the 3-WI method has been described in detail elsewhere (Ohta et al., 1996; Okazawa and Vafaee, 
2001). In brief, the method based on a 2-compartment model expressed by the following 
equation was used: 
 M (t )=  K 1 C a ( t ) ⊗  e - k 2 t   +  V 0 C a (t) 
, where K1 (mL min-1 g-1) and k2 (min-1) are rate constants for the tracers, M (Bq g-1) is the 
radioactivity in brain tissue, and Ca (Bq mL-1) is an arterial input function. The time delay of 
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arterial input was corrected automatically in the program, and a time constant of τ = 4 sec was 
used for internal dispersion correction (Ohta et al., 1996; Meyer, 1989; Iida et al., 1986). A 
distribution volume of 0.9 was used in the calculation of CBF (Herscovitch and Raichle, 1985). 
V0 images (mL 100g-1) were calculated simultaneously from data of each condition in the 3-WI 
method. 
 
Co-registration of PET and MRI 
Subjects underwent a high-resolution MRI scan (124 slices, 1.3 mm thick) using a Signa 
Horizon LX scanner (1.5T, General Electric Medical System, Milwaukee, WI). Co-registration 
of individual PET and MRI images was performed using an automatic procedure (Woods et al., 
1993) that uses the CBF image in each condition. The MRI image of each subject was 
transformed into Talairach space automatically (Collins et al., 1994; Talairach and Tournoux, 
1988). The baseline CBF image co-registered to MRI was then transformed into Talairach space 
using the individual spatial transformation parameter, which combined the two parameters from 
co-registration of PET to MRI and transformation of MRI into Talairach space. V0 images were 
also transformed into Talairach space in accordance with the same individual parameter 
(Okazawa and Vafaee, 2001). 
 
Statistical Data Analysis 
Global values for each parametric image of the 11 subjects were obtained using a template 
generated from the MRI averaged in Talairach space; i.e. the global mean values inside the 
brain template not including ventricles, after transformation of each CBF and V0 image 
(Okazawa and Vafaee, 2001). The same template was applied to all parametric images of all 
subjects. Global values thus obtained were compared between the conditions before and after 
rizatriptan administration. Analysis of variance (ANOVA) with post-hoc Fisher’s PLSD was 
used for the comparison. 
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Regional values were calculated using multiple regions of interest (ROIs) drawn on 
cortical territories of the bilateral middle cerebral arteries in Talairach space using individual 
MRI to avoid including outside of gray matter. The same ROIs were applied to all parametric 
images in each subject. Regional values for each parametric image were averaged and 
compared between different conditions by ANOVA. A probability value of less than 0.05 was 
considered to indicate a statistically significant difference. CBF and V0 differences at clusters of 
voxel level were also analyzed between different conditions using statistical parametric 
mapping (SPM2) (Friston et al., 1990, 1991). Details for the SPM comparison of multiple 
images were described elsewhere (Okazawa and Vafaee, 2001). In brief, after global 
normalization of absolute values, the t test was applied pixel-by-pixel to compare the regional 
differences in CBF and V0 obtained from the different conditions. The resulting t value for each 
pixel was then converted to a normal standard distribution (z-value), independent of the degree 
of freedom from error, constituting a statistical parametric map, as reported by Friston et al. 
(1991). In SPM analysis, each image was smoothed using a Gaussian filter (10 mm FWHM) 
and the pixel values were normalized so that the global mean of each parameter should be 50 
(mL min-1 100g-1) for CBF and 2 (mL 100g-1) for V0. To identify the regions showing 
significant differences, the height threshold (u) was set at p = 0.001 and the extent threshold (k) 
was set at k = 100 voxels. 
Physiological variables were compared across conditions using paired t-test. 
 
RESULTS 
Table 1 shows the average values of the physiological variables measured in the 11 
subjects during scanning at baseline and after rizatriptan administration. No physiological 
parameters were significantly changed after drug administration except for the systolic blood 
pressure. 
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Figure 1 shows average images of CBF and V0 obtained from the 11 healthy volunteers at 
baseline and at each time point after drug administration. Both CBF and V0 decreased at 40 to 
60 min after oral administration of rizatriptan. At 70 min from the baseline scan, V0 almost 
recovered from the reduction while global CBF was still diminished from baseline level. Both 
parameters returned to the baseline level 80 min after treatment. 
The changes and difference in global CBF and V0 from the baseline values are presented 
in Figure 2. Significant decreases were observed in CBF from 50 to 70 min and in V0 from 40 
to 50 min after rizatriptan administration, recovering such reductions later in the experiment. 
Table 2 shows the changes in global and regional CBF and V0 after medication. Both global and 
regional CBF showed significant decrease after rizatriptan administration. Approximately 10 % 
reduction of global CBF was observed between 50 and 70 min, and about 8 to 10 % reduction 
of regional CBF was observed between 40 and 70 min after drug administration. In both 
analyses, CBF recovered almost to baseline value 80 min after medication. V0 also showed 
significant global and regional reductions; however, its recovery was earlier than CBF and no 
significant difference was observed at 60 min or later. Maximal changes in CBF and V0 are 
shown in Table 3. The maximal reduction of CBF was – 13.0 % in global and – 13.5 % in the 
middle cerebral artery cortices. Similar degree of reduction was observed in V0, although 
regional reduction tended to be greater. The time at which the maximal change occurred tended 
to be earlier in V0 than in CBF in both global and regional values although the difference was 
not significant. 
SPM analysis did not show any significant regional differences in both CBF and V0 
between the different conditions after global normalization. 
 
DISCUSSION 
5-HT1B/1D receptor agonist, rizatriptan, which is used for migraine treatment, caused a 
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reduction of CBF and V0 for a short period after administration. The absolute values of these 
parameters recovered almost to baseline 80 min after rizatriptan challenge. Triptans act on 
5-HT1B receptors eliciting their vasoconstrictor effect upon the cephalic arteries and increasing 
their vascular resistance (Feniuk et al., 1989; Parsons et al., 1989; Longmore et al., 1992; De 
Vries et al., 1999a). Such response causes changes in blood flow and velocity in the dural and 
cerebral arteries. During the migraine attack, triptans-driven vasoconstriction acts on the cranial 
arteries which are expected to be dilated, resulting in a common carotid artery (CCA) blood 
flow decrease (Feniuk et al., 1989; den Boer et al., 1991). The present study showed a transient 
but significant decrease in both CBF and V0 observed during a short period of time after oral 
administration of the drug. This indicates a prompt vasoconstrictor effect of rizatriptan (Tepper 
et al., 2002), followed by delayed recovery of CBF and V0 in smaller arteries in cerebral tissue 
including arterioles and precapillaries. 
We did not assess directly the vasoconstrictor effect of the drug on the major arteries; 
however, CBF was measured based on the 2-compartment model, which minimizes influence of 
the vascular volume on regional CBF (Okazawa and Vafaee, 2001). V0 images calculated from 
the same dynamic data are an estimate of regional blood volume derived by model analysis. V0 
values obtained in grey matter by this method have been demonstrated to represent arterial to 
capillary blood volume in the brain, which may include little fraction of venous capillary 
volume but are not influenced by radioactivity in the large vessels (Ohta et al., 1996; Okazawa 
and Vafaee, 2001). Thus, reductions of regional CBF and V0 are expected to reflect changes in 
small arteries in cerebral cortex not influenced by radioactivity in major vessels. The complete 
recovery in the late phase of this study could have been induced by the mechanism of 
hemodynamic autoregulation. Oral administration of rizatriptan might have caused gradual 
vasoconstriction, and thus the CBF reduction would have occurred sluggishly, which would not 
cause immediate autoregulatory recovery of CBF via vasodilation of arterioles. Only a 
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significant reduction of CBF or perfusion pressure would cause autoregulatory hemodynamic 
response to take place and this presumably occurred in the last stage of our experiment. The 
arterial perfusion pressure, which is expected to be proportionally correlated with CBF to V0 
ratio (Okazawa et al., 2003), was mostly reduced at 70 min from the rizatriptan administration. 
This suggests that the reduction of arterial perfusion pressure may have continued until cerebral 
autoregulation driven vasodilatory reaction in arterioles resulted in CBF recovery. It is also 
possible that recovery from the significant reduction of CBF and blood volume in the later 
phase could have been caused by the declining pharmacological effects of the drug. However, 
the recovery was relatively prompt and the high plasma concentration of rizatriptan is expected 
to continue during almost 50 to 150 min after treatment (Vyas et al., 2000), indicating 
autoregulatory response seems more likely to explain this reaction. 
Triptans have been used for migraine treatment, and several investigations reported that 
their vasoconstrictor effect counteracted vasodilatory changes in migraine headache (Friberg et 
al., 1991; Caekebeke et al., 1992). Both animal experiments and isolated human arteries, as well 
as clinical studies reported their direct vasoconstrictor effect on various vessels (Feniuk et al., 
1989; Parsons et al., 1989; Longmore et al., 1992), and the drug-induced vasoconstriction lasted 
for 1.5 hour after drug administration in patients (de Hoon et al., 2000). In the latter study, the 
change in diameter of the CCA at 1.5 hour from drug administration was significant but 
relatively small, and the resistance of the CCA was not different compared with placebo 
treatment. From these results, it can be inferred that CBF, as compared to baseline, may not 
have been changed at the time points at which those parameters were measured in their study, 
which is consistent with the present study that showed no change in CBF between baseline and 
80 min after treatment. 
The mean maximal reductions in CBF and V0 from baseline were approximately 13 % 
both in global and regional CBF, and about 13 and 17 % in global and regional V0, respectively. 
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However, focal differences in CBF and V0 were not observed at SPM analysis, suggesting that 
rizatriptan did not cause any regional effects on specific cortical regions and acted mainly on 
the large vessels causing global changes as reported in the previous studies (Feniuk et al., 1989; 
Williamson et al., 1997; De Vries et al., 1999a, 1999b). The direct effect of the drugs on 5-HT1B 
receptors in the smooth muscles of the large vessels is hence confirmed by the absolute changes 
in CBF and V0. The CBF change was not caused by changes in systemic blood pressure nor 
blood gas because these parameters did not change after treatment. Although the systolic blood 
pressure was significantly increased after drug intake, which is caused by vasoconstriction of 
large vessels, the mean blood pressure did not change significantly as previously reported 
(Létienne et al., 2003). Since flow-mediated vascular dilatation is inversely related to resting 
arterial diameter (Celermajer, 1992), cerebral arterioles would have driven the recovery of CBF 
even though larger vessels remained constricted. 
In the current study, the earlier response of V0 as compared to CBF may reveal a more 
independent response of cerebral arterioles to the vasoconstriction caused by triptans. This is 
presumably due to the flow-induced vasodilatation in the smaller arteries known to be not 
affected by triptans (de Hoon et al., 2000). A small but significant decrease of CBF in earlier 
phase after treatment may have caused the vasodilatory response in cerebral circulation. Such 
response may have led the delayed changes in CBF mediated by cerebral autoregulation 
because of continuous vasoconstrictor effect in the major arteries on which triptans mainly act. 
This continuous vasoconstrictor effect may have caused slow supply of arterial blood into 
cerebral circulation and delay of response in CBF. 
In conclusion, administration of triptans causes reduction in CBF and arterial-to-capillary 
blood volume, which is consistent with the therapeutic vasoconstrictor effect of the drug. Such 
reduction recovers in a short period of time, presumably induced by hemodynamic 
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Average images of CBF (upper row) and V0 (bottom row) obtained from 11 healthy volunteers 
in Talairach space. Images of baseline and 60 min after rizatriptan administration were mean of 
all subjects. Other images were average of four subjects at 40 min and six subjects at remaining 
time after treatment. CBF was decreased up to 60 min after oral administration of rizatriptan 
and the reduction was gradually recovered in later phase. V0 also decreased until 50 min after 
treatment, and then tended to increase from the minimal reduction, which was earlier recovery 




The time-dependent changes and differences in global CBF and V0 before and after rizatriptan 
administration. Significant decreases were observed during 50 to 70 min in CBF and during 40 
to 50 min in V0 after treatment as compared to baseline. The reduction was recovered in later 
phase of the experiment. V0 was also showed significant difference between 40-50 min and 
70-80 min. *p < 0.01, †p < 0.05, compared by ANOVA with post-hoc Fisher’s PLSD. 
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Table 1. Physiological data in 11 healthy volunteers (Mean ± SD) 
 Baseline  Rizatriptan  Difference1)  
pH 7.41 ± 0.02 7.41 ± 0.02 0.002 ± 0.019 
PaCO2 (mmHg) 43.7 ± 4.0 44.9 ± 3.3 1.3 ± 4.2 
PaO2 (mmHg) 96.8 ± 9.4 99.4 ± 4.8 2.5 ± 9.0 
tO2c 19.9 ± 1.8 20.5 ± 1.8 0.6 ± 1.1 
Ht (%) 44.5 ± 4.0 45.5 ± 3.8 0.9 ± 1.9 
Mean Blood Pressure 
(mmHg) 
81.8 ± 10.9 84.7 ± 9.2 2.8 ± 9.2 
Systolic (mmHg) 113.5 ± 13.0 119.2 ± 12.1* 5.6 ± 5.6 
Diastolic (mmHg) 66.0 ± 10.5 67.5 ± 8.7 1.5 ± 7.6 
PaCO2: arterial carbon dioxide tension, PaO2: arterial oxygen tension, tO2c: arterial total oxygen 
consumption, Ht: hematocrit 
1) Mean ± SD of absolute change in each subject for each parameter 
* p < 0.01 comparing the two conditions (paired t-test). 
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Table 2. Global and regional changes in CBF and V0 before and after rizatriptan administration 
 Global Regional1)
 Absolute2) % Change Absolute2) % Change
CBF (mL min-1 100g-1)  
Baseline (n = 11) 45.8 ± 3.7  57.2 ± 4.9  
40 min (n = 4) 42.4 ± 3.0 -7.6 51.5 ± 4.5* -10.0 
50 min (n = 6) 41.2 ± 4.6* -9.6 52.6 ± 5.5* -8.0 
60 min (n = 11) 41.3 ± 2.6† -10.1 52.0 ± 7.2† -9.1 
70 min (n = 6) 41.3 ± 2.6* -9.9 52.4 ± 5.3* -8.3 
80 min (n = 6) 44.7 ± 4.1 -2.5 54.6 ± 4.0 -4.5 
V0 (mL 100g-1)     
Baseline (n = 11) 2.39 ± 0.40  2.62 ± 0.56  
40 min (n = 4) 2.14 ± 0.19* -10.5 2.16 ± 0.32* -17.7 
50 min (n = 6) 2.10 ± 0.35* -12.2 2.28 ± 0.37* -12.9 
60 min (n = 11) 2.35 ± 0.37 -2.0 2.41 ± 0.33 -8.1 
70 min (n = 6) 2.59 ± 0.19 8.2 2.65 ± 0.31 1.2 
80 min (n = 6) 2.60 ± 0.27 8.6 2.66 ± 0.36 1.5 
 
1) Average of cerebral cortex in bilateral middle cerebral artery territories 
2) Mean ± SD of absolute values in each condition for each parameter 
*p < 0.05, †p < 0.01 comparing between baseline and each time after rizatriptan administration 
(ANOVA with post-hoc Fisher's PLSD). 
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Table 3. Maximal changes in CBF and V0 (n = 11)1)
 CBF (mL min-1 100g-1) V0 (mL 100g-1) 
 Global Regional2) Global Regional2)
Baseline 45.8 ± 3.7 57.2 ± 4.9 2.39 ± 0.40 2.62 ± 0.56
Rizatriptan 39.9 ± 3.6* 49.4 ± 5.9* 2.09 ± 0.30† 2.19 ± 0.34†
Difference -13.0 % -13.5 % -12.8 % -16.6 % 
Time (min) 60.0 ± 14.8 56.8 ± 20.3 54.5 ± 12.1 53.6 ± 11.9
 
1) Mean ± SD before and after rizatriptan administration  
2) Average of cerebral cortex in bilateral middle cerebral artery territories 
*p < 0.00001, †p < 0.01 comparing between baseline and after rizatriptan administration (paired 
t-test). 
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